Pharma Penny Stocks Under Rs 100

The table below shows Pharma Penny Stocks Under Rs 100 based on the Highest Market Capitalization.

What Are Pharma Penny Stocks?

Pharma penny stocks in the Indian stock market are shares of small pharmaceutical companies priced below Rs 100. These stocks are highly speculative and involve significant risk due to their low market capitalization and potential for high volatility.

Investing in these stocks can be enticing due to the potential for substantial returns if a company succeeds in breakthrough developments or regulatory approvals. However, the risk of losing the entire investment is also considerably higher compared to more stable stocks.

Investors interested in pharma penny stocks should perform extensive due diligence, focusing on the company’s drug pipeline, market potential, and financial health. Understanding regulatory environments and market dynamics within India is crucial for assessing these investments.

Top 10 Pharma Penny Stocks Under Rs 100

The table below shows the Top 10 Pharma Penny Stocks Under Rs 100 based on 1 Year Return. 

Pharma Penny Stocks Under Rs 100 In India

The table below shows Pharma Penny Stocks Under Rs 100 In India based on 1 Month Return. 

Best Pharma Penny Stocks Under Rs 100

The table below shows the Best Pharma Penny Stocks Under Rs 100 based on the highest day Volume.

List Of Best Pharma Penny Stocks Under Rs. 100

The table below shows a List Of The Best Pharma Penny Stocks Under Rs. 100 based on PE Ratio.

Who Should Invest In Pharma Penny Stocks Under Rs 100?

Investors who should consider pharma penny stocks under Rs 100 are those with high-risk tolerance, speculative investment strategies, and a thorough understanding of the pharmaceutical industry. Such investors must be prepared for significant volatility and the potential for both high returns and substantial losses.

How To Invest In The Pharma Penny Stocks Under Rs 100?

To invest in pharma penny stocks under Rs 100, research and select potential companies with promising pipelines or technologies. Use a reliable broker to buy shares, diversify your portfolio to mitigate risk, and stay updated on pharmaceutical industry news and regulatory changes affecting these stocks.

Performance Metrics Of Pharma Penny Stocks Under Rs 100

The performance metrics of pharma penny stocks under Rs 100 can be highly volatile, reflecting the speculative nature of these investments. Key indicators include share price fluctuations, trading volume, and financial health metrics such as earnings per share and revenue growth.

Investors should also consider the success rates of clinical trials, FDA approvals, and partnership developments as performance indicators. These metrics provide insights into a company’s potential to succeed in the competitive pharmaceutical market, impacting stock performance significantly.

Benefits Of Investing In Pharma Penny Stocks Under Rs 100

The main benefit of investing in pharma penny stocks under Rs 100 is the potential for high returns. These stocks often represent small companies that can experience significant growth if they achieve breakthroughs or gain regulatory approvals.

• High Return Potential: Pharma penny stocks can yield substantial profits if the company successfully brings a new drug to market or partners with larger pharmaceutical firms. Such events can dramatically increase a stock’s value overnight.
• Low Entry Cost: With shares priced under Rs 100, these stocks allow investors to buy a larger quantity of shares with a smaller initial investment, potentially maximizing gains if the stock value increases.
• Market Movements: These stocks are sensitive to market news and regulatory events, offering opportunities for quick gains from market reactions to positive news such as successful drug trials or government approvals.
• Diversification: Adding pharma penny stocks to a diversified investment portfolio can provide a balance to more stable investments. It introduces a higher-risk, higher-reward component that could yield returns uncorrelated with the broader market.
• Innovative Exposure: Investing in these stocks offers exposure to innovative medical research and potential breakthrough treatments that could revolutionize health care and generate significant financial returns if successful.

Challenges Of Investing In Pharma Penny Stocks Under Rs 100

The main challenges of investing in pharma penny stocks under Rs 100 include high volatility, limited liquidity, and significant regulatory risks. Additionally, these stocks often suffer from a lack of information and a higher potential for fraud, making them risky investments.

• High Volatility: Pharma penny stocks under Rs 100 are extremely volatile. Their prices can swing wildly based on news or market sentiment, making them unpredictable and increasing the risk of substantial losses for investors not prepared for such fluctuations.
• Limited Liquidity: These stocks often have lower trading volumes, which can make it difficult to buy or sell large quantities without affecting the stock price. This lack of liquidity can be a significant barrier when trying to exit positions at favorable prices.
• Regulatory Risks: The pharmaceutical industry is heavily regulated. Delays in drug approval processes or negative results from clinical trials can severely impact the stock’s value. Investors must be mindful of the regulatory environment and its potential effects.
• Lack of Information: Small pharmaceutical companies under Rs 100 often lack the visibility of larger companies. This scarcity of information can make it challenging for investors to perform thorough due diligence, assess the company’s potential, and make informed investment decisions.
• Fraud and Mismanagement Risk: The lower levels of scrutiny and oversight in smaller, less-regulated companies can lead to higher risks of fraud or mismanagement. Investors may face challenges in verifying the authenticity of the company’s claims and the integrity of its management.

Introduction To Pharma Penny Stocks Under Rs 100

Morepen Laboratories Ltd

The Market Cap of Morepen Laboratories Ltd is ₹2,698.67 crore. The stock’s 1-month return is 19.56%, while its 1-year return is 1.76%. It is currently 104.87% away from its 52-week high.

Morepen Laboratories Ltd is a pharmaceutical company known for its focus on APIs, diagnostics, and formulations. It has built a strong reputation in producing high-quality bulk drugs and home diagnostic tools like blood pressure monitors and glucose meters.

The company has a diversified product portfolio and is also active in international markets. It maintains compliance with global standards and continues to innovate in the wellness and pharmaceutical space, aligning with growing healthcare awareness.

Syncom Formulations (India) Ltd

The Market Cap of Syncom Formulations (India) Ltd is ₹1,611.16 crore. The stock’s 1-month return is 24.25%, while its 1-year return is 27.43%. It is currently 62.78% away from its 52-week high.

Syncom Formulations (India) Ltd is engaged in manufacturing and marketing a wide range of pharmaceutical formulations. It produces tablets, capsules, syrups, and injectables, catering to domestic and international healthcare demands.

The company aims to serve quality medicines at affordable prices. It has strengthened its presence in regulated and semi-regulated markets and works toward continuous improvement in its R&D and manufacturing capabilities.

Shukra Pharmaceuticals Ltd

The Market Cap of Shukra Pharmaceuticals Ltd is ₹883.2 crore. The stock’s 1-month return is -91.99%, while its 1-year return is 162.46%. It is currently 34.61% away from its 52-week high.

Shukra Pharmaceuticals Ltd operates in the formulation of tablets, capsules, and liquid medicines for various therapeutic segments. It serves both domestic and overseas clients with a strong emphasis on quality and compliance.

The company focuses on contract manufacturing and leverages its state-of-the-art facilities for bulk production. It aims to expand its footprint through innovation and strategic partnerships in the global pharma sector.

Sudarshan Pharma Industries Ltd

The Market Cap of Sudarshan Pharma Industries Ltd is ₹754.71 crore. The stock’s 1-month return is 20.95%, while its 1-year return is 299.54%. It is currently 70.6% away from its 52-week high.

Sudarshan Pharma Industries Ltd is involved in the contract manufacturing of pharmaceutical intermediates, specialty chemicals, and bulk drugs. It also offers technical consultancy and product development services for the pharma industry.

The company serves various sectors, including healthcare, agriculture, and cosmetics. It continues to diversify its operations and build strategic relationships, aiming to boost its global presence and technological capabilities.

Nectar Lifesciences Ltd

The Market Cap of Nectar Lifesciences Ltd is ₹547.87 crore. The stock’s 1-month return is 2.1%, while its 1-year return is -31.38%. It is currently 131.27% away from its 52-week high.

Nectar Lifesciences Ltd is a fully integrated pharmaceutical company focusing on APIs, formulations, and phytochemicals. It has a strong infrastructure base and exports its products to several regulated and emerging markets.

The company emphasises quality manufacturing, regulatory compliance, and sustainability. Its research-driven approach supports long-term growth and operational excellence across diverse product segments.

IND Swift Laboratories Ltd

The Market Cap of IND Swift Laboratories Ltd is ₹520.96 crore. The stock’s 1-month return is 8.81%, while its 1-year return is -23.3%. It is currently 116.43% away from its 52-week high.

IND Swift Laboratories Ltd engages in the manufacturing and marketing of APIs and pharmaceutical products. It caters to domestic and global markets with a strong focus on innovation, quality control, and global regulatory approvals.

The company operates multiple facilities and has built a solid pipeline of molecules. Its goal is to improve patient outcomes while aligning with global healthcare needs through affordable and accessible solutions.

Medico Remedies Ltd

The Market Cap of Medico Remedies Ltd is ₹474 crore. The stock’s 1-month return is -0.16%, while its 1-year return is 18.75%. It is currently 39.76% away from its 52-week high.

Medico Remedies Ltd specialises in the manufacturing and export of pharmaceutical formulations. It serves a wide range of therapeutic categories, including anti-infectives, cardiovascular, and gastrointestinal medicines.

The company focuses on international business development and adheres to stringent quality norms. It is known for its customer-centric approach and operational efficiency in the global pharma supply chain.

ZIM Laboratories Ltd

The Market Cap of ZIM Laboratories Ltd is ₹414.51 crore. The stock’s 1-month return is 9.47%, while its 1-year return is -13.63%. It is currently 54.46% away from its 52-week high.

ZIM Laboratories Ltd is known for its innovative drug delivery systems, especially oral dispersible and modified release formulations. It offers contract development and manufacturing services for global pharmaceutical companies.

The company prioritises innovation, compliance, and scalability in its operations. With a robust R&D infrastructure, it seeks to develop user-friendly and effective drug delivery platforms to enhance patient outcomes.

Valiant Laboratories Ltd

The Market Cap of Valiant Laboratories Ltd is ₹387.05 crore. The stock’s 1-month return is 11.35%, while its 1-year return is -42.08%. It is currently 92.97% away from its 52-week high.

Valiant Laboratories Ltd is engaged in the manufacturing of active pharmaceutical ingredients (APIs), with a focus on bulk production and backward integration. It has a key product portfolio catering to domestic and global pharmaceutical companies.

The company emphasises sustainability and cost-efficiency in manufacturing. Its vision includes expanding capacity, enhancing quality processes, and building strategic collaborations in the highly regulated pharma space.

Gennex Laboratories Ltd

The Market Cap of Gennex Laboratories Ltd is ₹303.19 crore. The stock’s 1-month return is 8.62%, while its 1-year return is -22.55%. It is currently 117.55% away from its 52-week high.

Gennex Laboratories Ltd focuses on the production of APIs and intermediates used in manufacturing a wide range of medicines. It caters to pharmaceutical manufacturers in India and international markets.

The company maintains quality and consistency through regulatory-compliant processes. It aims to expand its presence by improving its product mix and capacity utilisation, keeping pace with evolving healthcare demands.

Top 10 Pharma Penny Stocks Under Rs  100- FAQs

Here are some of the Best Stock Research Articles listed based on Top Sectors (Industries), Market Cap, and Fundamental Analysis Factors:

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.